TopNews

Roche's phase III IMmotion151 study of Tecentriq & Avastin to treat advanced/metastatic RCC meets co-primary endpoint

Pronto Consult observes India’s 2025 healthcare shift from reactive protection to aspirational prevention

Peethaambaran Kunnathoor, Chennai

Saturday, January 10, 2026, 08:00 Hrs [IST]

Pronto Consult, a premier pharma market research company based in Mumbai, has released a comprehensive year-end analysis revealing that Indian healthcare in 2025 was defined by a deeply emotional commitment

To access the full article, please log in or subscribe.

Pharma Services

Tenders & Projects

Tenders & Enquires Pharma Projects

Corporate

Company Profile Corporate Results Corporate X-ray Pharmabiz Studies of Top Companies

US FDA Update

US FDA: ANDA US FDA: Warnings US FDA: Approved NMEs US FDA: Approved NMEs US FDA: REFUSAL

Export & Import

Drug Export Procedures Drug Units With WHO GMP Certification Pharma Export Data Import Reg. Update

Pharma Laws & Documents

Notifications Pharma Regulations Patent Laws and Amendments Patent Scan Documents New Drug Approvals Notified Prices

Labs & Govt Bodies

Govt Recognised In-House R&D Units AICTE Boards & Committees List of Indian CROs List of CROs (International) Govt & approved labs of India List of State Drugs Controllers